Gemcitabine for the treatment of ovarian cancer

Christina S. Chu, MD
Last Modified: April 21, 2002

Question:

Dear OncoLink "Ask The Experts,"
Have you or any of your colleagues used Gemzar in the treatment of ovarian cancer? I would like to know of any stats on the success of this chemotherapy for ovarian cancer.

Answer:

Christina S. Chu, MD, Assistant Professor of the Division of Gynecologic Oncology at the University of Pennsylvania Health System, responds:

Gemcitabine (brand name Gemzar®) is generally used as a second-line treatment for recurrent or persistent ovarian cancer. In general, the rate of response to this chemotherapy is about 15-20%. This means that 15-20% of patients with recurrent or persistent disease will have shrinkage of their tumor after treatment with gemcitabine.

Blogs

Christina’s Resource Roundup: Pet Cancer Awareness Month
by Christina Bach, MSW, LCSW, OSW-C
November 3, 2011

Christina’s Resource Round-Up March 2012: Co-Pay Assistance
by Christina Bach, MSW, LCSW, OSW-C
March 2, 2012

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Want up to date Cancer Treatment News? Subscribe to our eNewsletter. Subscribe Now